Keyword: Xolair

Sanofi's Dupixent picked up its important asthma approval on Friday, setting the drug up for a multibillion-dollar peak sales boost.

Roche and Novartis want to keep aging Xolair competitive for as long as possible, and they recently took a big step forward in doing that.

Xolair, Nucala, Cinqair, Fasenra and Dupixent will need to take a 50% to 68% discount off the list price to achieve cost-effectiveness, says ICER.

It hasn’t been an easy summer for AstraZeneca in the respiratory department, but the British drugmaker has finally come up with a win.

Roche’s Xolair has seen competitors encroach on its territory over the last few years. But now, it’s ready to carve out a new niche of its own.

GlaxoSmithKline is taking direct aim at severe asthma challenger Xolair from Novartis.

Roche managed 6% growth in the third quarter, but performance from key cancer meds highlighted biosimilar erosion ahead.

New meds are encroaching on a corner of the market for Novartis’ broader severe asthma treatment Xolair. But in response, the company is making it easier to diagnose the patient population it still has on lockdown.

Xolair-maker Novartis wants to create a support community for patients with chronic urticaria, or hives. And it’s funding a digital platform to do it.